ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS
Boost For Lilly, Blow For Pfizer
Executive Summary
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.
You may also be interested in...
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.
Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod
Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.
CDK4/6 Market: Is A Shakeup Underway?
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.